ASX:IMMBiotechs
Immutep H1 2026 Loss Worsening Challenges Bullish Revenue Growth Narratives
Immutep H1 2026 Results: Losses Widen as Revenue Steps Up
Immutep (ASX:IMM) has posted its H1 2026 numbers with revenue of A$6.0 million and a basic EPS loss of A$0.0305, alongside a net loss of A$44.9 million that keeps the biotech firmly in loss-making territory. Over recent halves, the company has seen revenue move from A$3.1 million in H1 2025 to A$1.9 million in H2 2025 and now A$6.0 million in H1 2026. EPS has shifted from a loss of A$0.0154 in H1 2025 to a loss of A$0.0268 in H2 2025...